Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q2 2024 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q2 2024 Earnings Call Transcript August 6, 2024Harmony Biosciences Holdings, Inc. beats earnings expectations.
Harmony Biosciences Holdings Inc. (HRMY)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Vivo Capital Albert Cha And Frank Kung | 2,606,247 | $78,630,472 | 7.26% | |
| 2. | Citadel Investment Group Ken Griffin | 684,318 | $20,645,874 | +18% | 0% |
| 3. | Renaissance Technologies Jim Simons | 595,800 | $17,975,286 | +57% | 0.03% |
| 4. | D E Shaw D. E. Shaw | 310,004 | $9,352,820 | +11% | 0% |
| 5. | Millennium Management Israel Englander | 307,420 | $9,274,861 | +52% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.00 | 339,476 | Large Shareholder | 10,651,120 | 2020-08-21 | Filing | |
| $34.30 | 3,922 | Director | 42,702 | 2020-08-26 | Filing | |
| $34.20 | 823 | Director | 38,780 | 2020-08-25 | Filing | |
| $24.00 | 132,503 | Large Shareholder | 4,409,803 | 2020-08-21 | Filing | |
| $34.30 | 3,057 | Director | 37,957 | 2020-08-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.00 | 11,979 | 0 | 2024-03-15 | Filing | ||
| $32.00 | 194 | 0 | 2024-03-08 | Filing | ||
| $59.96 | 2,834 | 2,571,024 | 2022-12-14 | Filing | ||
| $60.00 | 130 | Director | 2,147,943 | 2022-12-14 | Filing | |
| $60.13 | 6,320 | Director | 2,148,073 | 2022-12-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,218,033 | $362,342,466 | 99.55% | |
| 2. | 6,003,327 | $193,907,461 | 0% | |
| 3. | 5,276,825 | $170,441,447 | 0.01% | |
| 4. | 3,674,764 | $118,694,878 | 0% | |
| 5. | 1,360,447 | $43,942,438 | 0% |
News See All
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q1 2024 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. beats earnings expectations. Reported EPS is $0.666, expectations were $0.64. Harmony Biosciences Holdings, Inc.
5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we discuss 5 most undervalued biotech stocks to buy according to hedge funds.
10 Biotech Stocks with Huge Potential
In this article, we will take a look at the 10 biotech stocks with huge potential.
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q4 2023 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. misses on earnings expectations. Reported EPS is $0.45 EPS, expectations were $0.74. Harmony Biosciences Holdings, Inc.
18 High Growth Low PE Stocks
When value stocks came back with a vengeance in 2022, value investors cheered what they thought was the beginning of a long bull run of value stocks.
5 Best Healthcare Stocks For the Long-Term
In this piece, we will take a look at the five best healthcare stocks for the long term.
16 Most Undervalued Small-Cap Stocks To Buy According To Hedge Funds
In this article, we will take a look at the 16 most undervalued small-cap stocks to buy according to hedge funds.
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q3 2023 Earnings Call Transcript
Operator: Good morning. My name is Ashley, and I'll be your conference operator today.
12 Cheap Biotech Stocks Smart Investors Are Piling Into
In this piece, we will take a look at 12 cheap biotechnology stocks that smart investors are piling into.
Billionaire Hedge Funds
